Generically Speaking: A Hatch-Waxman Litigation Bulletin
By Oren Langer, Christopher Pinahs, and Bernard Pound
The Summer 2022 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue we review Q2 cases and issue(s) presented:
- Novartis Pharms. Corp. v. Accord Healthcare, Inc.
Gilenya® (fingolimod HCl)
The Federal Circuit granted Defendants’ petition for panel rehearing, vacated its prior decision, and reversed the district court’s judgment that the asserted claims were not invalid for inadequate written description.
- Bausch Health Ireland, Ltd. v. Padagis Israel Pharms., Ltd.
Duobrii® (halobetasol propionate / tazarotene)
The court granted summary judgment of no inequitable conduct.
- Astellas US LLC v. Hospira, Inc.
After bench trial, the Court found that the patents-in-suit were not infringed by Hospira.
Relevant ANDA updates highlighted in this issue:
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.